HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
MONDAY, Aug. 8, 2022 (HealthDay News) -- The risk for cancer is higher for men than women at most shared anatomic sites, according to a study published online Aug. 8 in Cancer.
Sarah S. Jackson, Ph.D., from the National Cancer Institute in Rockville, Maryland, and colleagues conducted prospective cohort analyses involving 171,274 male and 122,826 female participants in the National Institutes of Health-AARP Diet and Health Study (1995 to 2011) to examine the extent to which behaviors, anthropometrics, lifestyles, and medical history collectively explain the male predominance of risk at 21 shared cancer sites. Data were included for 26,693 incident cancers (17,951 and 8,742 in men and women, respectively).
The researchers found that for thyroid and gallbladder cancers only, incidence was significantly lower in men than women. The risks were higher for men than women at most other sites (adjusted hazard ratio range, 1.3 to 10.8), with the strongest increases seen for bladder cancer, gastric cardia cancer, larynx cancer, and esophageal adenocarcinoma (hazard ratios, 3.33, 3.49, 3.53, and 10.80, respectively). A statistically significant proportion of the observed male excess for esophageal adenocarcinoma and cancers of the liver, other biliary tract, bladder, skin, colon, rectum, and lung was explained by risk factors, although the proportion of the male excess that was explained by risk factors was modest (ranging from 50 to 11 percent for lung cancer and esophageal adenocarcinoma, respectively).
"Understanding the sex-related biologic mechanisms that lead to the male predominance of cancer at shared anatomic sites could have important implications for etiology and prevention," the authors write.
One author disclosed financial ties to Merck.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at firstname.lastname@example.org with any questions.
Updated on September 21, 2022